유럽의 유전자 검사 서비스 시장 : 범위, 부문, 동향, 경쟁 분석(2021-2031년)

The European genetic testing services market is projected to grow significantly, reaching approximately USD 3,284.96 million by 2031, up from USD 1,049.33 million in 2023. This growth represents a compound annual growth rate (CAGR) of 15.3% from 2023 to 2031.

Executive Summary and Market Analysis

The market for genetic testing services in Europe is divided into several key regions, including Germany, the UK, France, Italy, Spain, and the Rest of Europe. The demand for genetic testing has surged, with a wide array of tests now available to screen for various genetic disorders. Treatments for numerous rare genetic conditions are becoming more accessible, and genetic testing is increasingly recognized for its role in carrier testing, newborn screening, and predictive and pre-symptomatic testing. European nations have initiated various programs to enhance public awareness regarding the advantages of genetic testing, aiming to ensure high-quality standards that yield accurate and reliable results for patients.

Market Segmentation Analysis

The genetic testing services market can be categorized based on service type, disease, and service provider:

1. Service Type: The market is segmented into predictive testing, carrier testing, prenatal testing, newborn screening, diagnostic genetic testing, and others. In 2023, predictive testing emerged as the leading segment in terms of market share.

2. Disease: The market is also divided by disease type, including cancer, cardiovascular diseases, metabolic disorders, and other conditions. The cancer segment held the largest market share in 2023, reflecting the high demand for genetic testing in oncology.

3. Service Provider: The market is segmented by service provider into hospital-based laboratories, diagnostic laboratories, and other providers. Hospital-based laboratories accounted for the largest share of the market in 2023.

Market Outlook

The field of personalized medicine, which leverages genetic and environmental data to tailor healthcare to individual patients, is rapidly evolving and being integrated into various healthcare systems. This approach is grounded in the understanding that each patient is unique and may require specific pharmacological treatments. The completion of the Human Genome Project (HGP) in 2003, along with the decreasing costs of genome sequencing, has paved the way for personalized medicine. Companies specializing in molecular diagnostics are well-positioned to capitalize on the growing repository of personalized data at the molecular level.

In Germany, personalized medicine, referred to as individualized medicine (IM), has gained significant traction. The German Federal Ministry of Education and Research (BMBF) identified personalized medicine as a priority area by 2010, launching the "Individualized Medicine" Action Plan. Additionally, the 100,000 Genomes Project has bolstered the National Health Service's reputation as a leading healthcare system, further supporting the growth of the genetic testing services market. France has also made strides in this area with its "Genomic Medicine France 2025" initiative, which aims to position the country as a leader in genomic medicine through substantial public investment.

The advancement of drug discovery is crucial for enhancing the effectiveness of personalized medicines in diagnosing diseases. Genomics is rapidly becoming a pivotal area in medical science, transforming research methodologies for disease diagnosis and treatment. Genetic testing plays a vital role in pharmacogenomics, which accelerates drug discovery and development processes.

Country Insights

The European genetic testing services market includes key countries such as the UK, Germany, France, Italy, Spain, and others. Germany held the largest market share in 2023. Medical genetics has become integral to clinical practice, providing healthcare professionals with valuable diagnostic tools for managing diseases and implementing preventive measures. A study published in 2022 highlighted that rare diseases affect around four million individuals in Germany. The increasing prevalence of rare diseases, coupled with the development of specialized testing kits, is driving market growth. For instance, in 2020, Germany reported approximately 69,697 new breast cancer cases, accounting for 11.1% of all cancer cases, with a significant portion of these cases linked to BRCA mutations.

The German government has taken steps to include BRCA genetic testing in its national cancer strategy, enhancing screening and risk-reduction options for women at high genetic risk. The introduction of noninvasive prenatal testing as a publicly reimbursed service in 2022 further illustrates the country's commitment to advancing genetic testing. Factors such as government initiatives, rising consumer awareness, and increased healthcare spending are expected to propel market growth in Germany.

Company Profiles

Key players in the European genetic testing services market include Eurofins Scientific SE, Exact Sciences Corp, Laboratory Corp of America Holdings, 23andMe Holding Co, Ambry Genetics Corp, Quest Diagnostics Inc, Illumina Inc, F. Hoffmann-La Roche Ltd, NeoGenomics Inc, Centogene NV, Ancestry Genomics Inc, Gene By Gene Ltd, SIVOTEC BioInformatics LLC, Progenesis, Fulgent Genetics, Inc, VERITAS INTERCONTINENTAL, and GeneDx, LLC. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers.

Table Of Contents

1. Introduction

• 1.1 Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Secondary Research
• 3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macroeconomic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country-level data:

4. Europe Genetic Testing Services Market Landscape

• 4.1 PEST Analysis

5. Europe Genetic Testing Services Market - Key Market Dynamics

• 5.1 Market Drivers
  • 5.1.1 Rising Prevalence of Genetic Diseases
  • 5.1.2 Increasing Awareness and Acceptance of Personalized Medicines
  • 5.1.3 Growing Preference for Direct-To-Consumer (DTC) Genetic Testing
• 5.2 Market Restraints
  • 5.2.1 Social and Ethical Implications of Genetic Testing
  • 5.2.2 Affordability of Genetic Services
• 5.3 Market Opportunities
  • 5.3.1 Regulatory Support
• 5.4 Future Trends
  • 5.4.1 Artificial Intelligence-Powered Genetic Testing
• 5.5 Impact Analysis:

6. Genetic Testing Services Market - Europe Analysis

• 6.1 Europe Genetic Testing Services Market Revenue (US$ Million), 2021-2031
• 6.2 Europe Genetic Testing Services Market Forecast Analysis

7. Europe Genetic Testing Services Market Analysis - by Service Type

• 7.1 Predictive Testing
  • 7.1.1 Overview
  • 7.1.2 Predictive Testing: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.2 Carrier Testing
  • 7.2.1 Overview
  • 7.2.2 Carrier Testing: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.3 Prenatal Testing
  • 7.3.1 Overview
  • 7.3.2 Prenatal Testing: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.4 New-born Screening
  • 7.4.1 Overview
  • 7.4.2 New-born Screening: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.5 Diagnostic Genetic Testing
  • 7.5.1 Overview
  • 7.5.2 Diagnostic Genetic Testing: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.6 Others
  • 7.6.1 Overview
  • 7.6.2 Others: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Genetic Testing Services Market Analysis - by Disease

• 8.1 Cancer
  • 8.1.1 Overview
  • 8.1.2 Cancer: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 8.2 Cardiovascular Diseases
  • 8.2.1 Overview
  • 8.2.2 Cardiovascular Diseases: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 8.3 Metabolic Diseases
  • 8.3.1 Overview
  • 8.3.2 Metabolic Diseases: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 8.4 Other Diseases
  • 8.4.1 Overview
  • 8.4.2 Other Diseases: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Genetic Testing Services Market Analysis - by End User

• 9.1 Hospital-Based Laboratories
  • 9.1.1 Overview
  • 9.1.2 Hospital-Based Laboratories: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 9.2 Diagnostic Laboratories
  • 9.2.1 Overview
  • 9.2.2 Diagnostic Laboratories: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 9.3 Other End User
  • 9.3.1 Overview
  • 9.3.2 Other End User: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Europe Genetic Testing Services Market - Country Analysis

• 10.1 Europe
  • 10.1.1 Europe Genetic Testing Services Market - Revenue and Forecast Analysis - by Country
    • 10.1.1.1 Europe Genetic Testing Services Market - Revenue and Forecast Analysis - by Country
    • 10.1.1.2 United Kingdom: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.2.1 United Kingdom: Europe Genetic Testing Services Market Share - by Service Type
      • 10.1.1.2.2 United Kingdom: Europe Genetic Testing Services Market Share - by Disease
      • 10.1.1.2.3 United Kingdom: Europe Genetic Testing Services Market Share - by Cancer Disease
      • 10.1.1.2.4 United Kingdom: Europe Genetic Testing Services Market Share - by End User
    • 10.1.1.3 Germany: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.3.1 Germany: Europe Genetic Testing Services Market Share - by Service Type
      • 10.1.1.3.2 Germany: Europe Genetic Testing Services Market Share - by Disease
      • 10.1.1.3.3 Germany: Europe Genetic Testing Services Market Share - by Cancer Disease
      • 10.1.1.3.4 Germany: Europe Genetic Testing Services Market Share - by End User
    • 10.1.1.4 France: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.4.1 France: Europe Genetic Testing Services Market Share - by Service Type
      • 10.1.1.4.2 France: Europe Genetic Testing Services Market Share - by Disease
      • 10.1.1.4.3 France: Europe Genetic Testing Services Market Share - by Cancer Disease
      • 10.1.1.4.4 France: Europe Genetic Testing Services Market Share - by End User
    • 10.1.1.5 Spain: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.5.1 Spain: Europe Genetic Testing Services Market Share - by Service Type
      • 10.1.1.5.2 Spain: Europe Genetic Testing Services Market Share - by Disease
      • 10.1.1.5.3 Spain: Europe Genetic Testing Services Market Share - by Cancer Disease
      • 10.1.1.5.4 Spain: Europe Genetic Testing Services Market Share - by End User
    • 10.1.1.6 Italy: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.6.1 Italy: Europe Genetic Testing Services Market Share - by Service Type
      • 10.1.1.6.2 Italy: Europe Genetic Testing Services Market Share - by Disease
      • 10.1.1.6.3 Italy: Europe Genetic Testing Services Market Share - by Cancer Disease
      • 10.1.1.6.4 Italy: Europe Genetic Testing Services Market Share - by End User
    • 10.1.1.7 Rest of Europe: Europe Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.7.1 Rest of Europe: Europe Genetic Testing Services Market Share - by Service Type
      • 10.1.1.7.2 Rest of Europe: Europe Genetic Testing Services Market Share - by Disease
      • 10.1.1.7.3 Rest of Europe: Europe Genetic Testing Services Market Share - by Cancer Disease
      • 10.1.1.7.4 Rest of Europe: Europe Genetic Testing Services Market Share - by End User

11. Genetic Testing Services Market - Industry Landscape

• 11.1 Overview
• 11.2 Growth Strategies in Genetic Testing Services Market
• 11.3 Organic Growth Strategies
  • 11.3.1 Overview
• 11.4 Inorganic Growth Strategies
  • 11.4.1 Overview

12. Company Profiles

• 12.1 Eurofins Scientific SE
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Exact Sciences Corp
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
• 12.3 Laboratory Corp of America Holdings
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
• 12.4andMe Holding Co
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments
• 12.5 Ambry Genetics Corp
  • 12.5.1 Key Facts
  • 12.5.2 Business Description
  • 12.5.3 Products and Services
  • 12.5.4 Financial Overview
  • 12.5.5 SWOT Analysis
  • 12.5.6 Key Developments
• 12.6 Quest Diagnostics Inc
  • 12.6.1 Key Facts
  • 12.6.2 Business Description
  • 12.6.3 Products and Services
  • 12.6.4 Financial Overview
  • 12.6.5 SWOT Analysis
  • 12.6.6 Key Developments
• 12.7 Illumina Inc
  • 12.7.1 Key Facts
  • 12.7.2 Business Description
  • 12.7.3 Products and Services
  • 12.7.4 Financial Overview
  • 12.7.5 SWOT Analysis
  • 12.7.6 Key Developments
• 12.8 F. Hoffmann-La Roche Ltd
  • 12.8.1 Key Facts
  • 12.8.2 Business Description
  • 12.8.3 Products and Services
  • 12.8.4 Financial Overview
  • 12.8.5 SWOT Analysis
  • 12.8.6 Key Developments
• 12.9 NeoGenomics Inc
  • 12.9.1 Key Facts
  • 12.9.2 Business Description
  • 12.9.3 Products and Services
  • 12.9.4 Financial Overview
  • 12.9.5 SWOT Analysis
  • 12.9.6 Key Developments
• 12.10 Centogene NV
  • 12.10.1 Key Facts
  • 12.10.2 Business Description
  • 12.10.3 Products and Services
  • 12.10.4 Financial Overview
  • 12.10.5 SWOT Analysis
  • 12.10.6 Key Developments
• 12.11 Ancestry Genomics Inc
  • 12.11.1 Key Facts
  • 12.11.2 Business Description
  • 12.11.3 Products and Services
  • 12.11.4 Financial Overview
  • 12.11.5 SWOT Analysis
  • 12.11.6 Key Developments
• 12.12 Gene By Gene Ltd
  • 12.12.1 Key Facts
  • 12.12.2 Business Description
  • 12.12.3 Products and Services
  • 12.12.4 Financial Overview
  • 12.12.5 SWOT Analysis
  • 12.12.6 Key Developments
• 12.13 SIVOTEC BioInformatics LLC
  • 12.13.1 Key Facts
  • 12.13.2 Business Description
  • 12.13.3 Products and Services
  • 12.13.4 Financial Overview
  • 12.13.5 SWOT Analysis
  • 12.13.6 Key Developments
• 12.14 Progenesis
  • 12.14.1 Key Facts
  • 12.14.2 Business Description
  • 12.14.3 Products and Services
  • 12.14.4 Financial Overview
  • 12.14.5 SWOT Analysis
  • 12.14.6 Key Developments
• 12.15 Fulgent Genetics, Inc
  • 12.15.1 Key Facts
  • 12.15.2 Business Description
  • 12.15.3 Products and Services
  • 12.15.4 Financial Overview
  • 12.15.5 SWOT Analysis
  • 12.15.6 Key Developments
• 12.16 VERITAS INTERCONTINENTAL
  • 12.16.1 Business Description
  • 12.16.2 Products and Services
  • 12.16.3 Financial Overview
  • 12.16.4 SWOT Analysis
  • 12.16.5 Key Developments
• 12.17 GeneDx, LLC
  • 12.17.1 Key Facts
  • 12.17.2 Business Description
  • 12.17.3 Products and Services
  • 12.17.4 Financial Overview
  • 12.17.5 SWOT Analysis
  • 12.17.6 Key Developments

13. Appendix

• 13.1 About The Insight Partners
• 13.2 Glossary of Terms